Search Results for 'Rbv Daclatasvir'

Rbv Daclatasvir published presentations and documents on DocSlides.

Management of HCV in Co-Infected Patients

danika-pritchard
22 Slides

Marie-Louise Vachon, MD, . MSc. Division of . Inf...

The Resource Based View of the Firm (RBV)

celsa-spraggs
36 Slides

B290. The object of strategic analysis…. Explai...

Ombitasvir-

min-jolicoeur
23 Slides

Paritaprevir. -. Ritonavir (. Technivie. ). Prepa...

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in

conchita-marotz
10 Slides

SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Fel...

OBV/PTV/r

kittie-lecroy
7 Slides

+ DSV + RBV. No randomisation. Open-label. TOPAZ-...

TURQUOISE-II

pasty-toler
18 Slides

OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . ...

Simeprevir in

ellena-manuel
14 Slides

Genotype . 1 . (. Viral . Relapsers. ). PROMISE ....

Sofosbuvir in

giovanna-bartolotta
9 Slides

Genotype . 2. . or 3 . FUSION. Trial. Phase . ...

Peginterferon alfa-2a (

tatyana-admore
46 Slides

Pegasys. ). Prepared by: David Spach, MD & H....

Ombitasvir-Paritaprevir-Ritonavir

sherrill-nordquist
9 Slides

. and Dasabuvir +/- . RBV in . GT1b. PEARL-II. P...

Are Pan-Genotypic Therapies Ready for Prime Time?

lois-ondreau
21 Slides

3. Rd. International . HIV/Hepatitis . Coinfecti...

Ombitasvir-Paritaprevir

tatiana-dople
9 Slides

-. Ritonavir . and Dasabuvir . + RBV in . GT1. SA...

No randomisation

tatiana-dople
6 Slides

N = 100. W12. W24. Arm B: . compensated cirrhosis...

Ledipasvir-Sofosbuvir (

lindy-dunigan
127 Slides

Harvoni. ). Prepared by: . David H. Spach, MD and...

OBV/PTV/r

conchita-marotz
5 Slides

OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open labe...

MK3 + RBV

jane-oiler
5 Slides

N = 45. N = 49. W24. W16. MK3. > . 18 years. H...

2013 Asilomar HIV Medical Update

luanne-stotts
74 Slides

David Spach, MD. Clinical Director, Northwest AET...

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

debby-jeon
10 Slides

. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...

ALLY-1

stefany-barnette
6 Slides

Design. Objective. SVR. 12. (HCV RNA < 25 IU/...

Sofosbuvir, Ribavirin, GS

min-jolicoeur
7 Slides

-. 0938 in GT 1-4. QUANTUM. Phase . 2b. Treatment...

Not randomised Open-label

cheryl-pisano
0 Slides

18-70 years. HCV genotype 1 or 3. Naïve or failu...

The Resource Based View of the Firm (RBV)

alida-meadow
0 Slides

B290. The object of strategic analysis…. Explai...

Ledipasvir-Sofosbuvir RBV in HCV GT 1,4 and Advanced Liver Disease

alida-meadow
0 Slides

SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment ...

HIV Pipeline Doravirine 2

giovanna-bartolotta
0 Slides

(MK-1439; DOR). . NNRTI. Merck. Filed with USFDA...

Global Hepatitis C Guidelines 2014: recommendations for a public health approach

olivia-moreira
0 Slides

Gottfried . Hirnschall. Background . HCV infectio...

Resistance to Direct Acting Antiviral Therapy

tawny-fly
0 Slides

Resistance to HCV DAAs: What is the threat level...

Community Pharmacy Considerations for HIV

tawny-fly
0 Slides

& HCV . Therapy. Larry Pineda, . PharmD. , . ...

HIV Pipeline Cabotegravir-LA

liane-varnes
0 Slides

(GSK-744; CAB). For . PrEP. INI. ViiV. Topical mi...

SOF/VEL 400/100 mg qd N = 75

danika-pritchard
0 Slides

W24. SOF/VEL. >. 18 years. Chronic HCV infect...

Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir

vamput
59 Slides

Prepared by: . Sophie . Woolston. , MD and David H...

Use of HCV DAAs with HIV Regimens

robaut
13 Slides

Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....

HIV-HCV Coinfection in the era of effective antiviral therapy

mia
21 Slides

Mark Sulkowski, . MD. Professor of Medicine. Medic...

Practical management of PI therapy

TropicalParadise
86 Slides

in Hepatitis C . Paris . Februari. 2012. Ola . We...

Clinical Group

summer
3 Slides

CC By 010 Therapeutic Challenges College of Pharma...

Treatment of Chronic Hepatitis C Virus Infection in Adults

tracy
28 Slides

www.hivguidelines.org. APRIL 2023. NYSDOH AIDS Ins...

Hepatitis C in PWIDS London:

obrien
135 Slides

PARTNERSHIP TOWARDS ELIMINATION OF A MAJOR PUBLIC ...

TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I

eloise
18 Slides

20. th. International AIDS Conference. • . Melb...

Boceprevir with PEG + RBV in Genotype 1

caroline
7 Slides

SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. ...

EASL 2019 HCV Conference Update

sophia
54 Slides

April 10. –14. , 2019. Vienna, Austria. Disclaim...

3D (Paritaprevir-Ritonavir-

ava
9 Slides

Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEA...